May 8 |
Teva Pharmaceutical reports mixed Q1 results; reaffirms FY24 outlook
|
May 8 |
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
|
May 8 |
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
|
May 8 |
Investor Sentiment Falls Further, Dow Gains For Fifth Session
|
May 8 |
Uber, Lyft And 3 Stocks To Watch Heading Into Wednesday
|
May 7 |
Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
|
May 7 |
20 States with the Highest Fertility Rates in the US
|
May 7 |
Teva Pharmaceutical Q1 2024 Earnings Preview
|
May 6 |
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
|
May 6 |
Teva Pharmaceutical Industries (NYSE:TEVA) shareholders have earned a 54% return over the last year
|